StockIQ.techBristol-Myers Squibb Company (BMY) Stock Analysis
Free AI-powered analysis and research for Bristol-Myers Squibb Company stock
Sector: Healthcare
BMY snapshot
Data as of 3 Nov 2026 close. Updated daily.
Bristol-Myers Squibb Company scores 80/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 72% of its 52-week range, up 35.0% over the past year. Latest reported figures show a profit margin of 18.9%, return on equity of 46.6% and revenue growth of +5.7%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bullish: +8
- Low P/E (13.4): +10
- Good Profit Margin (18.9%): +5
- High Debt (2.02 D/E): -10
- Excellent ROE (46.6%): +8
- High P/B (5.59): -5
- Above MA200: +4
- Strong Momentum (+35.0% over 1 year): +8
- Low Volume (0.2x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BMY report
Bristol-Myers Squibb Company (BMY) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BMY Now →📰 Latest Update
BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shifts
Mon, November 2, 2026 at 9:57 PM UTC 3 min read
Bristol Myers Squibb (NYSE:BMY) reported Q3 2026 results with revenue of $13.07 billion, exceeding analysts' expectations by 6.9%, and a non-GAAP profit of $1.35 per share, beating estimates by 12.4%. The company raised its full-year revenue guidance to approximately $50 billion but lowered its adjusted EPS guidance to $6.45, citing increased R&D expenses and margin pressure. Despite these challenges, management highlighted strong growth in its portfolio and positive momentum in its pipeline advancements.